Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer.

Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer.

Blog Article

BackgroundLiquid biopsies enable the detection of circulating tumor DNA (ctDNA).However, the clinical significance of KRAS-mutated ctDNA for pancreatic cancer has been inconsistent with respect sonics empire to its prognostic and predictive potential.Methods and findingsA total of 422 blood samples were collected from 78 patients undergoing treatments for localized and metastatic pancreatic ductal adenocarcinoma.

KRAS mutation in tissues and KRAS ctDNA levels in plasma were determined by RASKET and droplet digital polymerase chain reaction.Longitudinal monitoring of KRAS ctDNA was performed to assess its significance for predicting recurrence and prognosis and for evaluating therapeutic responses to chemotherapy compared with carbohydrate antigen 19-9 (CA19-9).In 67 tumor tissues, discrepancies in point mutations of KRAS were rarely observed among individual patients, solo-jec 9 vaccine for dogs implying that one targeted point mutation of KRAS can be determined in tumor tissues prior to longitudinal blood monitoring.

One-time blood assessment of KRAS-mutated ctDNA before surgery or chemotherapy was not clearly associated with recurrence and prognosis.Sequential blood monitoring was performed in 39 patients who underwent surgery for potentially resectable tumors.Increased CA19-9 levels were significantly associated with recurrence, but not prognosis (PConclusionsOur study showed for the first time that detection of KRAS ctDNA levels within a short period enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer.